[Angiotensin receptor vaccines].

Hiroyuki Sasamura, Tatsuhiko Azegami, Hiroshi Itoh

Research output: Contribution to journalReview articlepeer-review


Recent clinical studies have shown that RAS inhibitors are effective not only for the prevention of end-organ damage in hypertensive patients, but also for prevention of new-onset hypertension, diabetes mellitus, and atrial fibrillation. Vaccines against the RAS have been developed since the 1950s, and a recent phase IIa placebo-controlled study has confirmed that an angiotensin vaccine causes a significant decrease in blood pressure in hypertensive patients. The results of animal experiments from our and other laboratories have suggested that vaccination against the angiotensin type 1 (AT1) receptor causes a significant decrease in blood pressure in animal models of hypertension, and also ameliorates hypertensive end-organ damage. The angiotensin receptor may therefore be an important target for the development of vaccines for the prevention of hypertension and related complications.

Original languageEnglish
Pages (from-to)1633-1638
Number of pages6
JournalNihon rinsho. Japanese journal of clinical medicine
Issue number9
Publication statusPublished - 2011 Sept 1
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of '[Angiotensin receptor vaccines].'. Together they form a unique fingerprint.

Cite this